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factors predicting vascular disease progression (e.g. arterial aneurysms, dissections, and ruptures) in EDS
patients are still missing. Recently, applanation tonometry derived augmentation index (AIx), an indirect
marker of arterial stiffness, has shown to be positively associated with progression of aortic disease in
Marfan syndrome. In this study, we assessed aortic AIx in patients with EDS and matched healthy
controls. METHODS We performed noninvasive applanation tonometry in 61 adults with EDS (43 women
and 18 men aged 39.3 ± 14.6 years) and 61 age-, gender-, height-, and weight-matched healthy controls.
Radial artery pulse waveforms were recorded and analyzed using the SphygmoCor System (AtCor Medical,
Sydney, NSW, Australia). Calculated AIx was adjusted to a heart rate of 75/min. Groups were compared
and association between AIx and EDS was determined by univariate and multivariate regression analysis.
RESULTS EDS patients were categorized in classical type EDS (34%), hypermobile type EDS (43%),
vascular type EDS (5%), or remained unassignable (18%) due to overlapping features. EDS patients
showed a significantly increased aortic AIx compared to healthy controls (22.8% ± 10.1 vs 14.8% ±
14.0, p < 0.001). EDS showed a positive association with AIx; independent of age, sex, height, blood
pressure, medication, and pack years of smoking. CONCLUSIONS Patients with EDS showed elevated
AIx, indicating increased arterial stiffness when compared to healthy controls. Further investigations are
needed in order to assess the prognostic value of increased AIx for cardiovascular outcomes in patients
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Abstract
Background: Ehlers-Danlos Syndrome (EDS) comprises a heterogeneous group of diseases characterized by joint
hypermobility, connective tissue friability, and vascular fragility. Reliable prognostic factors predicting vascular disease
progression (e.g. arterial aneurysms, dissections, and ruptures) in EDS patients are still missing. Recently, applanation
tonometry derived augmentation index (AIx), an indirect marker of arterial stiffness, has shown to be positively associated
with progression of aortic disease in Marfan syndrome. In this study, we assessed aortic AIx in patients with EDS and
matched healthy controls.
Methods:We performed noninvasive applanation tonometry in 61 adults with EDS (43 women and 18 men aged 39.3 ±
14.6 years) and 61 age-, gender-, height-, and weight-matched healthy controls. Radial artery pulse waveforms were recorded
and analyzed using the SphygmoCor System (AtCor Medical, Sydney, NSW, Australia). Calculated AIx was adjusted to a heart
rate of 75/min. Groups were compared and association between AIx and EDS was determined by univariate and multivariate
regression analysis.
Results: EDS patients were categorized in classical type EDS (34%), hypermobile type EDS (43%), vascular type EDS (5%), or
remained unassignable (18%) due to overlapping features. EDS patients showed a significantly increased aortic AIx
compared to healthy controls (22.8%± 10.1 vs 14.8%± 14.0, p< 0.001). EDS showed a positive association with AIx;
independent of age, sex, height, blood pressure, medication, and pack years of smoking.
Conclusions: Patients with EDS showed elevated AIx, indicating increased arterial stiffness when compared to healthy
controls. Further investigations are needed in order to assess the prognostic value of increased AIx for cardiovascular
outcomes in patients with EDS.
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Background
Ehlers-Danlos Syndrome (EDS) represents a heterogeneous
group of heritable connective tissue disorders characterized
by joint hypermobility, connective tissue friability, as well as
skin and vascular fragility. The combined prevalence of all
EDS subtypes appears to be nearly 1 to 5000 individuals
world- wide [1]. The current international classification of
EDS distinguishes 13 clinical subtypes, for which molecular
mutations have been identified in 19 different genes [2].
Vascular fragility with easy bruising is common in all
patients with EDS, but its severity varies between EDS
subgroups [3]. An increased bleeding tendency including
menometrorrhagia, gum bleeding, and peri-operative
hemorrhage has been described in many EDS-patients of
varying EDS subtypes [3]. Spontaneous aneurysms, dis-
sections and ruptures of medium to large sized arteries,
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caused by defects in type III collagen, are a clinical hall-
mark of the vascular type of EDS (vEDS). These life-
threatening complications result in a reduced life span
with a median age of approximately 51 years [4]. Major
vascular events have also been described in EDS sub-
types with other molecular defects, including defects of
collagen I and V or molecules involved in collagen fold-
ing (FKBP22), processing (ADAMTS-2) or modification
(LH1) [3].
Recent advances in surgical and endovascular manage-
ment of progressive arterial disease in EDS patients have
been associated with good clinical outcomes [5–8].
Nevertheless, due to the difficult handling of fragile tis-
sue and vessels during the operation, a sufficient risk-
benefit assessment becomes crucial. Given that spontan-
eous arterial rupture can also occur in non-dilated arter-
ies, prognostic factors for identification of vascular high-
risk patients are indispensable, yet undetermined to date
[9].
Arterial tonometry derived augmentation index (AIx)
is measured by pulse wave analysis, and is an indirect
surrogate measure of arterial stiffness [10]. It has been
shown to be an independent predictor of mortality and
cardiovascular events in patients with hypertensive, car-
diovascular and renal disease [11]. Furthermore, recent
findings suggest that the AIx is elevated in patients with
Marfan syndrome and correlates with progression of
aortic disease [12, 13]. Therefore, in a first step, the AIx
of EDS patients was compared to age-, gender-, weight-,
and height-matched healthy controls and possible pre-
dicting factors were assessed.
Methods
Study design and participants
This study was part of a recently published prospective
parallel-cohort study, which our group conducted in
order to assess the prevalence of obstructive sleep ap-
noea in patients with EDS [14]. For this purpose, 100
adult patients with EDS were one-to-one matched to
100 healthy adult controls according to sex, age, weight
and height. Study procedures included structured inter-
views (including short-form 36), level-3 respiratory poly-
graphy and arterial tonometry.
Between April and December 2015, EDS patients have
been recruited from three different sources: University
Children’s Hospital Zurich EDS database, University
Hospital Zurich EDS database, and an international net-
work based on EDS associations. EDS diagnosis and
categorization followed the Villefranche diagnostic cri-
teria [15]. Hypermobility was assessed according to the
Beighton score [16]. EDS diagnosis was confirmed either
by 1) gene analysis, 2) pathological electron microscope
study findings or biochemical analysis of collagen in cul-
tivated fibroblasts suggestive for specific EDS subtypes
or 3) increased ratio of deoxypyridinoline to pyridioline
crosslinks in biochemical urine analysis for kyphoscolio-
tic EDS (kEDS: formerly EDS VIA) [17–19]. Healthy
control subjects were recruited from the local population
in Zurich to specifically match (one-to-one matching)
the patients with EDS in terms of sex, age (± 3 years),
height (±20 cm) and weight (±15 kg). If subjects were
aged 18 years or above, physically and intellectually cap-
able to adhere to the study protocol, and were not preg-
nant, we considered them eligible. 61 patients with EDS
agreed to the applanation tonometry at the study site in
Zurich and thus were included in the study. Accordingly,
61 matched healthy controls were also investigated and
included in this study. All participants provided written
informed consent to participate in the study. All proce-
dures were reviewed and approved by the Cantonal Eth-
ics Committee Zurich (registration number KEK-ZH-




Before pulse wave analysis, subjects had to rest ten mi-
nutes in supine position. Subsequently, radial artery
pulse waveforms were recorded using the SphygmoCor
System (AtCor Medical, Sydney, NSW, Australia). Ap-
proximately ten radial pulse waves were measured and a
corresponding central aortic pressure waveform was
generated using a validated mathematical transfer func-
tion [20]. The inflection point of the aortic pressure
waveform corresponds to the onset of the reflected wave
returning from peripheral arteries and divides the aortic
pressure wave into an early and late systolic peak. This
inflection point can be determined with an algorithm.
The AIx quantifies the augmentation of central aortic
pressure, hence representing a measure of peripheral ar-
terial wave reflection. AIx can be calculated as the differ-
ence between the second (P2) and the first systolic peak
pressure (P1) and is expressed as percentage of central
pulse pressure (PP):
AIx %ð Þ ¼ P2 − P1ð Þ=PP½   100:
Since AIx is influenced by heart rate [21, 22], the index
is adjusted to a heart rate of 75 bpm. SphygmoCor Px
software adjusts the AIx at an inverse rate of 4.8% for
each 10 bpm increment. To ensure a high measurement
quality, only measurements with an operator index of 80
and above were accepted. The measurements were con-
ducted by two trained, unblinded researchers.
Data analysis and statistics
All data are presented as mean ± standard deviation (SD)
or median (quartiles) unless otherwise stated. Groups
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were compared by independent t-test, Wilcoxon rank
sum test or ANOVA. Univariate regression analysis was
used to investigate association between AIx and EDS as
well as possible and known (prespecified) predictors for
AIx such as age, sex, height, weight, BMI, blood pressure
(BP), smoking status, and use of medication. To further
investigate the independent association between AIx and
EDS, multivariate analysis was performed including all
variables showing p-value < 0,1 in univariate regression
analysis. We assessed eight possible clinical predictors
with multiple regression analysis. Using a probability
level of 0.05 the observed R2 of 0.6 in the final model led
to a statistical power of 100% [23, 24]. Residual analysis
of the model was performed to check the regression as-
sumption. A two-sided p-value of < 0,05 was considered
statistically significant.
Results
Study participants and baseline characteristics
A total of 65 EDS patients underwent pulse wave ana-
lysis. Due to insufficient measurement quality, four sub-
jects had to be excluded. Subsequently, 61 healthy
controls were matched. A total of 122 subjects entered
the final analysis of pulse wave analysis measurement
(Fig. 1). EDS Patients were categorized in classical type
EDS (34%), hypermobile type EDS (43%), vascular type
EDS (5%) or remained unassignable (18%) due to over-
lapping features although Villefranche inclusion criteria
were fulfilled. AIx measurements took place after mean
(SD) 10 ± 13.1 years after the initial EDS diagnosis. The
mean (SD) age in the EDS cohort and the healthy con-
trols was 39.3 ± 14.6 years and 35.6 ± 11.4 years, respect-
ively. Diastolic BP (80.6 ± 10.8 mmHg vs 76.1 ± 11.8
mmHg) and the number of patients using antihyperten-
sive drugs (16% vs 2%) or NSAIDs (21% vs 3%) was sig-
nificantly higher in the EDS cohort. The most important
class of antihypertensive drugs in EDS patients was ACE
inhibitor/ATII receptor blocker (7 out of 10 patients),
while one patient of the control group used a beta-
blocker. The detailed patients’ characteristics are shown
in Tables 1 and 2.
Pulse wave analysis
EDS patients showed a significantly increased aortic AIx
compared to healthy controls (22.8 ± 10.1% vs 14.8 ±
14.0%, p < 0.001) as shown in Fig. 2. The primary wave
pressure (P1 height) showed no statistical difference
(median (quartiles) 20 (16/23) mmHg vs 20 (17/24)
mmHg). While the time to the first aortic pressure peak
(T1) was comparable, the time to the second aortic pres-
sure peak (T2) and the ejection duration (ED) was sig-
nificantly shorter in the EDS cohort. EDS patients had a
significantly higher resting heart rate during the pulse
wave analysis. Patients suffering vascular type EDS
showed the highest AIx (mean (SD) 31.2 ± 14.1%), even
though there was no statistical difference between the
assessed EDS subtypes. Detailed information about the
results of pulse wave analysis are shown in Table 3.
Predictors of aortic AIx
AIx was positively associated with age, diastolic BP, pack
years of smoking, and use of antihypertensive drugs.
Male sex, weight and height were negatively associated
with AIx in univariate regression analysis (Table 4).
Table 5 presents the independent predictors of AIx ana-
lyzed by a multiple regression model. EDS showed a sig-
nificant, positive, and independent association with AIx
(Coef. (95% CI) of 3.85 (0.41 to 7.29), p = 0.029). While
age, diastolic BP and pack years of smoking were inde-
pendently associated with AIx, the use of medication
showed no independent association in the multiple re-
gression analysis. Height and male sex showed a nega-
tive, independent association with AIx. Due to strong
correlation between height and weight (r = 0.70, p <
0.001), weight was removed from the final model.
Discussion
This study investigated the applanation tonometry de-
rived augmentation index (AIx) in a well characterized
cohort of EDS patients. EDS patients showed a signifi-
cantly, independently increased AIx compared to
matched healthy controls, suggesting increased arterial
stiffness in EDS patients despite the known influencing
factors such as age, sex, BP and smoking history. Al-
though vascular EDS patients showed the highest AIx
(31.2 ± 14.1%), no significant overall differences of the
AIx could be observed between the different types of
EDS.
The aortic AIx is used as an indirect index of vascular
stiffness derived from aortic pressure waveform analysis
[25, 26]. It represents the ratio of the ejection pressure
from the heart and the reflection pressure from the ar-
terial system. In this study, the primary wave pressure
(P1), which represents the primary left ventricular ejec-
tion pressure, showed no difference between EDS pa-
tients and healthy controls, leading to the conclusion,
that the observed difference in AIx results from the ar-
terial reflection wave. These findings suggest that the in-
creased AIx might represent increased arterial stiffness
in EDS patients. This hypothesis is supported by the fact
that the time of the second aortic peak (T2) was signifi-
cantly shorter in the EDS cohort, while the time for the
first peak (T1) was comparable. The finding of an in-
creased AIx in EDS patients cannot be compared to
other studies yet due to missing literature on this topic.
However, since the AIx of our healthy controls (14.8 ±
14.0%) are comparable to expected reference values ob-
tained from larger unselected population-based studies
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the findings in EDS seems to be plausible [27]. Further-
more, AIx was positively correlated to female gender,
age, diastolic BP, and pack years of smoking, and was
also negatively correlated to height and weight as re-
ported in previous studies [27–30].
Literature about arterial stiffness and cardiovascular
risk in EDS patients is rare and the existing results are
incongruent due to inhomogeneous study populations
and different methods used to determine arterial
stiffness [31–35]. Population inhomogeneity is mainly
based on the fact that EDS is an umbrella term for clin-
ically diverse connective tissue disorders based on differ-
ent genetic defects [36].
Our results contradict in particular a recently pub-
lished study by Miller et al., reporting increased arterial
elasticity in patients with EDS measured by pulse wave
velocity (PWV) [35]. Nevertheless, this study only retro-
spectively analyzed a subset of EDS patients from the
Fig. 1 Study flow chart. The majority of the study participants were recruited by hospital-wide screening of electronic databases (Children’s
Hospital Zurich and University Hospital Zurich). 200 study participants were enrolled, and 122 participants were included in the final analysis. EDS,
Ehlers-Danlos syndrome. AIx, Augmentation Index
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Clinical and Molecular Manifestations of HDCT study
who had both orthostatic BP recordings and PWV mea-
surements [37]. There might be a selection bias, because
the authors focused especially on the connection be-
tween orthostatic intolerance (OI) and EDS patients.
The comparison of these results with our study has to
be done with caution, as only few information on study
population is available and the EDS patients were not
matched to a healthy control group. Nevertheless, we
have to point out that AIx is a measure of pressure wave
reflection, while PWV is the most commonly and uni-
versally acceptable measure of arterial stiffness. The as-
sessment of central/aortic pressures, PWR and AIx in
this specific population compared to healthy controls are
of great interest and should be the focus of future
research.
Vascular complications in patients with EDS are his-
torically attributed to impaired synthesis and processing
of diverse collagen types, leading to fragility of blood
vessel walls and perivascular connective tissue, thus a
decreased arterial stiffness would be suspected. However,
molecular pathomechanisms underlying development of
arterial aneurysms, dissections, rupture and bleeding are
poorly understood [3]. It is to mention that arterial stiff-
ness is not only determined by the arterial wall’s com-
position of elastin and collagen. For example, smooth
muscle cells behave as a stiff material linking fibrous
component and contribute to arterial stiffness especially
when contracted [38–40]. Furthermore, animal studies
suggest that effective arterial stiffness results from com-
plex interactions between smooth muscle cells and
extracellular matrix. For instance, increased fibronectin,
Table 1 Baseline characteristics of the 122 one-to-one matched study participants
EDS cohort (n = 61) Healthy control cohort (n = 61) p-value
Sex (f / m) 43 / 18 43 / 18 –
Caucasian, % 100 100 –
Age, years 39.3 ± 14.6 35.6 ± 11.4 0.13
Height, cm 168.5 (161.0/174.5) 169.0 (162.5/176.5) 0.47
Weight, cm 65.0 (54.0/76.0) 65.0 (58.0/75.5) 0.73
BMI, kg/m2 22.7 (20.4/25.9) 22.9 (20.8/24.7) 0.96
BSA, m2 1.3 (1.1/1.5) 1.3 (1.2/1.5) 0.81
Neck, cm 33 (31/37) 33 (32/37) 0.70
Waist, cm 73 (67/85) 76 (69.0/81.0) 0.87
Blood pressure systolic (office), mmHg 117.4 ± 14.2 112.8 ± 12.8 0.07
Blood pressure diastolic (office), mmHg 80.6 ± 10.8 76.1 ± 11.8 0.03
Pulse, min−1 76.7 (67/84.7) 69.0 (64.0/76.7) 0.025
Alcohol units per week, units 0 (0/1) 0 (0/2) 0.74
Current Smoker, n (%) 15 (25%) 9 (15%) 0.20
Diabetes, n (%) 3 (4.9%) 0 (0%) 0.08
Arterial hypertension, n (%) 10 (16%) 1 (2%) 0.004
Pack years of smoking, n 0 (0/3) 0 (0/1) 0.11
Antihypertensive drugs, n (%) 10 (16%) 1 (2%) 0.004
NSAIDs, n (%) 13 (21%) 2 (3%) 0.002
Lipid lowering drugs, n (%) 0 0 –
Antiplatelet drugs, n (%) 1 (1.64%) 0 0.32
Antidiabetic drugs, n (%) 0 0 –
EDS Ehlers-Danlos Syndrome; BMI Body-Mass-Index; BSA body surface area; NSAID non-steroidal anti-inflammatory drugs
Table 2 Aortic Augmentation Index @HR 75 in different EDS subtypes
EDS type Classical type Hypermobile type Vascular type Not assignablea p-value
N 21 (34%) 26 (43%) 3 (5%) 11 (18%) –
Beighton score 5.7 ± 2.5 5.4 ± 2.5 2.3 ± 1.5 5.5 ± 2.5 0.199
Aortic Augmentation Index @HR 75, % 22 ± 11 22 ± 11 32 ± 10 25 ± 11 0.451
aNot clearly attributable due to overlapping features, although Villefranche inclusion criteria are fulfilled. Patients fulfilling diagnostic criteria for more than one
EDS subtype were labeled “not assignable” for this study. EDS Ehlers-Danlos Syndrome; HR heart rate
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an extracellular protein, is associated with a cell dediffer-
entiation process leading to increased production of
extracellular matrix proteins by smooth muscle cells
[41]. Stewart et al. [42] found that the aortic AIx and
carotid-femoral pulse wave velocity increases after the
application of a nitric oxide synthase inhibitor, thus
pointing out the importance of basal nitric oxide on
functional regulation of central arteries in humans. Ni-
tric oxide synthesis could be altered in EDS patients
given the recent finding that markers of endothelial dys-
function such as VCAM-1, ICAM-1 and MCP-1 are in-
creased in vEDS patients [43].
Our EDS patients showed increased resting heart rate
and BP compared to healthy controls. Increased resting
Fig. 2 Box plots for aortic augmentation index adjusted to heart rate of 75/min by groups
Table 3 Pulse wave analysis in both cohorts
EDS cohort (n = 61) Healthy control cohort (n = 61) p-value
Aortic AIx (AP/PP) @HR 75, % 22.8 ± 10.1 14.8 ± 14.0 < 0.001
P1 height, mmHg 20 (16/23) 20 (17/24) 0.438
Peripheral T1, ms 113 (104/122) 109 (104/119) 0.288
Peripheral T2, ms 200 (191/212) 209 (202/221) 0.002
Peripheral AIx, % 80.4 ± 18.2 72.5 ± 17.2 0.017
End systolic pressure, mmHg 102 (92/109) 97 (91/105) 0.103
Ejection duration, ms 296 (276/309) 302 (288/316) 0.025
Heart rate, min−1 76 (67/83) 67 (63/72) < 0.001
Mean pressure systolic, mmHg 99 (91/107) 96 (90/102) 0.142
Mean pressure diastolic, mmHg 89 (82/96) 85 (79/91) 0.069
AIx Augmentation index; EDS Ehlers-Danlos Syndrome; HR heart rate
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sympathetic activity has already been described as part
of autonomic dysregulation in EDS patients [44]. The
connection between elevated BP, increased arterial stiff-
ness and vascular disease has been extensively reviewed
in the general literature about cardiovascular pathology.
Chronic elevated BP leads to decreased vascular disten-
sability that, in turn, increases pulsatile shear stress and
pressure leading to endothelial dysfunction and vascular
disease [45, 46]. Increased arterial wall stress in EDS pa-
tients compared to healthy controls has been reported
by Boutouyrie et al. [47] using high-resolution echo-
tracking systems.
Shingu et al. [48] found an elevated carotid AIx in pa-
tients with aortic aneurysm and dissection, which the
authors attributed to increased left ventricular afterload.
Whether an increased prevalence of aortic aneurysms
and dissections could be a reason for the increased AIx
in our EDS cohort remains unknown because study sub-
jects did not undergo vasculopathy evaluation. Depend-
ing on EDS subtypes, EDS patients suffer joint pain,
joint dislocation, muscle cramps and fatigue leading to
significantly reduced physical activity [49]. There are
several studies suggesting a link between decreased
physical activity and increased arterial stiffness [50, 51].
Even when only considering the number of reported
joint luxation in our EDS cohort (22% of all EDS pa-
tients), reduced daily activity as a cause for increase ar-
terial stiffness should be considered. In this study, EDS
patients used more NSAIDs and antihypertensive medi-
cation compared to healthy controls. The influence of
several medications, including antihypertensive and anti-
inflammatory drugs on arterial stiffness has been de-
scribed in literature [41], but no independent pharmaco-
logical influence on the AIx was observed in our study.
Furthermore, it is to mention that no EDS patient was
treated with Celiprolol, a cardioselective β-blocker that
has recently been shown to increase stiffness of the com-
mon carotid artery in vEDS patients [52].
Since medical and interventional management ad-
vances lead to improved survival and quality of life in
Table 4 Univariate regression analysis of possible predictors for aortic AIx (AP/PP) normalized for a heart rate of 75/min in all study
subjects (n = 122)
Variable Coefficient 95% Confidence Interval p-value
Age, years 0.43 0.27 to 0.59 < 0.001
Male sex, (yes/no) −13.36 −17.96 to −8.76 < 0.001
Height, cm −0.61 −0.80 to −0.42 < 0.001
Weight, kg −0.21 − 0.36 to − 0.06 0.007
BMI, kg/m2 0.19 −0.40 to 0.78 0.532
Ehlers-Danlos Syndrome, (yes/no) 8.10 3.59 to 12.60 0.001
Mean systolic blood pressure, mmHg 0.124 −0.05 to 0.30 0.168
Mean diastolic blood pressure, mmHg 0.42 0.22 to 0.61 < 0.001
Smoking, (yes/no) 2.78 −3.18 to 8.79 0.357
Pack years of smoking, n 0.41 0.12 to 0.69 0.006
Antihypertensive Drugs, (yes/no) 8.67 0.55 to 16.79 0.037
Antiplatelet Drugs, (yes/no) −5.88 −32.13 to 20.37 0.658
NSAID, (yes/no) 7.03 −0.07 to 14.19 0.052
AIx Augmentation index; BMI Body-Mass-Index; NSAID non-steroidal anti-inflammatory drugs
Table 5 Multivariate linear regression analysis of possible predictors for aortic AIx (AP/PP) normalized for a heart rate of 75/min in all
study subjects (n = 122)
Variable Coefficient 95% Confidence Interval p-value
Ehlers-Danlos Syndrome, (yes/no) 3.85 0.41 to 7.29 0.029
Height, cm −0.43 − 0.64 to − 0.23 < 0.001
Male sex, (yes/no) −8.00 −12.48 to −3.52 0.001
Age, years 0.32 0.18 to 0.46 < 0.001
Pack years of smoking, n 0.26 0.05 to 0.47 0.015
Mean diastolic blood pressure, mmHg 0.16 0.01 to 0.31 0.042
Antihypertensive drugs, (yes/no) 3.75 −1.82 to 9.33 0.185
NSAID, (yes/no) 1.00 −3.99 to 5.99 0.692
AIx Augmentation index; NSAID non-steroidal anti-inflammatory drugs
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EDS patients, the role of early identification of vascular
high-risk patients gains importance. To date, little is
known about prognostic factors that could predict the
chance of developing fatal cardiovascular events in pa-
tients with EDS. Pepin et al. [4] recently showed that the
natural course of vEDS varies with gender and type of mu-
tation in COL3A1. This group showed a 5-year survival
difference between males and females which was primarily
based on a higher death rate before age of 20 due to vas-
cular rupture. Vascular inflammation marker has been
shown to be significantly elevated in vascular EDS patients
compared to matched controls [53]. However, their poten-
tial to predict vascular complications in EDS patients are
still subject of ongoing investigation [43].
Increased applanation tonometry derived AIx has been
reported in patients with Marfan syndrom [13], a genetic
connective tissue disorder due to mutation in the fibril-
lin 1 gene [54]. These patients also suffer from fatal vas-
cular events like aortic dissection and rupture [55].
Mortensen et al. [13] conducted a longitudinal observa-
tional study to follow-up cardiovascular disease progres-
sion in 50 adult patients with Marfan syndrome for
almost 2 years. Beside baseline aortic root diameter, only
aortic AIx showed an independent association to aortic
disease progression. Furthermore, Kaplan-Meier curve
analysis presented a significantly lower rate of aortic root
disease in patients with lower AIx [12]. EDS and Marfan
syndrome are multisystemic disorders that primarily
affect the soft connective tissues. Even if these disorders
differ in genetic and molecular pathogenesis, there are at
least some clinical overlaps [36] suggesting that the in-
creased AIx might predict vascular disease progression
in EDS patients as reported in Marfan syndrome pa-
tients. In addition, the fact that the other “non-vascular”
EDS subtypes showed increased AIx as well, could point
out an increased risk for cardiovascular events beside
the vEDS-typical vascular complications. However, data
about the general cardiovascular risk in EDS patients
compared to the general population are lacking.
There are some limitations to our study. The patient
numbers of EDS subtypes, especially of vEDS, were rela-
tively small to allow statistical comparison of different
AIx values between different subtypes. Nonetheless, re-
lated to EDS incidence, the number of acquired patients
was considerable. Arterial stiffness was not the primary
outcome of this study, hence no specific power calcula-
tion for pulse wave analysis measurement were done.
However, the AIx difference measured in EDS patients
and healthy controls was considerably. In addition, our
study design did not allow a longitudinal follow-up of
cardiovascular events in EDS patients. Further longitu-
dinal studies assessing AIx and cardiovascular events in
EDS patients would be needed to show the clinical rele-
vance of increased AIx as a prognostic factor for
cardiovascular risk in these patients. Nevertheless, since
vEDS patients harbor the highest risk for fatal vascular
events and this subgroup presented the highest AIx in
our study, AIx already indicate potential as a possible
predictor for vascular high-risk patients.
Conclusion
This study showed increased applanation tonometry de-
rived AIx in patients with EDS suggesting elevated arterial
stiffness compared to healthy controls. Additional investi-
gations have to assess the predictive value of increased ar-
terial stiffness regarding general cardiovascular risk in
patients with EDS. Furthermore, prospective observational
studies are needed in order to evaluate whether AIx might
provide similar prediction of aortic disease progression as
it was shown in patients with Marfan syndrome.
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